EGFR and non-small cell lung carcinoma: In one prior network meta-analysis (NMA) evaluating these various first-line approaches to the therapy of NSCLC cases with advanced EGFR-mutated disease, the investigators identified that osimertinib in isolation exhibited the most favorable patient progression-free survival (PFS), while the combination of gefitinib and pemetrexed-based chemotherapy was linked to superior overall survival (OS) rates [11].